2026-10-06T04:07:47Z https://api.figshare.com/v2/oai

oai:figshare.com:article/34071953 2026-10-05T17:31:17Z category_7 category_12 category_13 category_21 category_873 category_734 category_132 category_134 portal_5 item_type_3 month_year_10_2026

<p>The original data and code used in this study.</p> Zhongbao Zuo (3594755) Chunli Yang (2087218) Lanlan Hu (8422443) Xiafen Ye (25316894) Yazhen Zhang (6531935) Lili Huang (125493) Miaochan Wang (12988513) Huaizhong Cui (11252132) Xiaoqiang Chen (214695) Kenv Pan (12988519) Jianfeng Bao (1967512) He He (5933444) Medicine Cell Biology Genetics Biotechnology Chemical Sciences not elsewhere classified Biological Sciences not elsewhere classified Infectious Diseases Virology six serological models scheuer scoring system s0 &# 8211 routine monitoring tool routine blood parameters like protein 1 hangzhou xixi hospital domestically produced device among serological models superior diagnostic efficacy better diagnostic efficacy liver stiffness measurement xlink "> non xlink "> among proven cld cohort fib &# 8209 underwent liver biopsy platelet ratio index corresponding auroc values apri ], fibrosis s2 ), 0 xlink "> platelet ratio liver fibrosis s3 ), s2 ). diagnostic performance prp ], liver biopsy 4 ], strongest correlation staged according serum chitinase s4 ). recent guidelines practical advantage october 2019 lower cost laboratory testing invasive assessment histological staging <div> <p>Background</p><p>Non-invasive assessment of liver fibrosis is essential for managing chronic liver disease (CLD). Serum chitinase-3-like protein 1 (CHI3L1) has been recommended in recent guidelines, while FibroTouch is a domestically produced device for liver stiffness measurement (LSM). However, no study has directly compared their diagnostic performance in CLD patients.</p> <p>Methods</p><p>This retrospective study included 235 patients with CLD who underwent liver biopsy, FibroTouch examination, and laboratory testing (including CHI3L1 and routine blood parameters) at Hangzhou Xixi Hospital between October 2019 and December 2024. Liver fibrosis was staged according to the Scheuer scoring system (S0–S4). The diagnostic performance of LSM, CHI3L1, and six serological models (aspartate aminotransferase-to-platelet ratio index [APRI], fibrosis-4 index [FIB-4], S-Index, Forns index, platelet ratio-to-RDW [PRP], and FIB-5) were evaluated using receiver operating characteristic (ROC) curve analysis, with liver biopsy as the reference standard.</p> <p>Results</p><p>Among the 235 patients, 125 (53.2%) had significant fibrosis (≥S2). LSM demonstrated excellent diagnostic accuracy, with area under the curve (AUROC) values of 0.86 for detecting significant fibrosis (≥S2), 0.91 for advanced fibrosis (≥S3), and 0.93 for cirrhosis (S4). CHI3L1 showed moderate diagnostic performance, with corresponding AUROC values of 0.72, 0.79, and 0.81. LSM exhibited the strongest correlation with histological staging (r = 0.70, p < 0.0001). Among serological models, APRI and FIB‑4 showed relatively better performance, while FIB‑5 performed poorly.</p> <p>Conclusions</p><p>In this biopsy-proven CLD cohort, LSM demonstrated superior diagnostic performance for liver fibrosis assessment compared to CHI3L1 and six serological models, with the strongest correlation with histological staging. Given its better diagnostic efficacy and lower cost, LSM offers a practical advantage as a routine monitoring tool in clinical practice, particularly in resource-constrained settings.</p></div> 2026-10-05T17:31:12Z Dataset Dataset 10.1371/journal.pone.0357883.s003 https://figshare.com/articles/dataset/_p_The_original_data_and_code_used_in_this_study_p_/34071953 CC BY 4.0